ASHP Releases AHFS Drug Information 2016 Edition

ASHP Releases AHFS Drug Information 2016 Edition


ASHP has released a new edition of AHFS Drug Information (AHFS DI), the nation’s leading compendium of unbiased and authoritative drug information. AHFS DI is the only printed compendium designated by the U.S. Congress as a source for reimbursement of off-label uses. The Centers for Medicare & Medicaid Services and numerous healthcare insurance providers recognize it as a definitive reference on the medically accepted uses of drugs. Unlike most compendia, recognition of the authority of AHFS DI in establishing medically accepted drug uses extends far beyond cancer drugs to include the full spectrum of drug therapy. Both the National Association of Boards of Pharmacy and the American College of Physicians have listed AHFS DI as a recommended item for inclusion in reference libraries. The 2016 edition of AHFS DI, which marks 58 years of continuous publication, contains extensively updated monographs and revised therapeutic guidelines, including revised recommendations for the treatment of HIV infections in adult and pediatric patients. It also presents new information on breakthrough oncology drugs approved as part of the Food and Drug Administration (FDA) Accelerated Approval Program. “AHFS DI is the gold standard for providing the critical, evidence-based data that healthcare practitioners need to make informed prescribing decisions,” said Gerald K. McEvoy, Pharm.D., editor-in-chief of AHFS DI and ASHP assistant vice president of drug information. “The 2016 edition is supported by more than 87,000 references and incorporates the expertise of hundreds of leading health professionals and guidance from numerous authoritative groups, providing the most trustworthy, evidence-based data on which to base therapeutic decisions.”

ASHP Health-System Pharmacy Press Releases and Announcements

Öffnungszeiten der Schufa